54004-20-5

Upstream product

• 1194-21-4 6-chloroisocytosine 
• 74-89-5 methylamine 
• 56-06-4 2,6-diaminopyrimidin-4-ol 

Downstream Products

• 142979-53-1 Methyl 4-(4-<2-amino-3,4-dihydro-6-(methylamino)-4-oxopyrimidin-5-yl>butyl)benzoate 
• 86296-75-5 2-amino-6-(methylamino)-5-nitrosopyrimidin-4(3H)-one 
• 142979-56-4 N-(4-(4-<2-Amino-3,4-dihydro-6-(methylamino)-4-oxopyrimidin-5-yl>butyl)benzoyl)-L-glutamic acid 
• 142979-55-3 Diethyl N-(4-(4-<2-amino-3,4-dihydro-6-(methylamino)-4-oxopyrimidin-5-yl>butyl)benzoyl)-L-glutamate 
• 868372-53-6 2-amino-5-mesityl-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 
• 868373-48-2 C₂₂H₃₀N₄O 
• 1304707-34-3 C₁₇H₂₀N₄O 
• 868372-54-7 2-amino-5-mesityl-3,7-dimethyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 

Relevant academic research and scientific papers

HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN

The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, or neuropathic pain).

Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor

A new class of pyrrolo[2,3-d]pyrimidin-4-one corticotropin-releasing factor 1 (CRF1) receptor antagonists has been designed and synthesized. In general, reported CRF1 receptor antagonists possess a sp 2-nitrogen atom as hy